Advanced Oncotherapy PLC Result of General Meeting (8000N)
January 22 2019 - 10:29AM
UK Regulatory
TIDMAVO
RNS Number : 8000N
Advanced Oncotherapy PLC
22 January 2019
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Result of General Meeting
Advanced Oncotherapy plc (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces that at the General Meeting held yesterday, all
resolutions were duly passed. As a result, the Directors now have
authority to issue 25,000,000 (twenty-five million) new Ordinary
Shares to the Placees as detailed in the Circular of this General
Meeting.
Application will be made for admission to trading on AIM
("Admission") of the 25,000,000 new Ordinary Shares deriving from
the Placing and it is expected that Admission will occur on or
around 28 January 2019.
Total voting rights
Following Admission, the Company's enlarged issued share capital
will comprise 194,566,092 Ordinary Shares, with voting rights. The
Company does not hold any Ordinary Shares in treasury. Therefore,
the total number of Ordinary Shares in the Company with voting
rights will be 194,566,092. This figure may be used by shareholders
in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change in their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
Advanced Oncotherapy Plc www.avoplc.com
Dr. Michael Sinclair, Executive Tel: +44 20 3617 8728
Chairman
Nicolas Serandour, CEO
Stockdale Securities (Nomad &
Joint Broker)
Antonio Bossi / David Coaten Tel: +44 20 7601 6100
Stifel Nicolaus Europe (Joint
Broker)
Jonathan Senior / Ben Maddison Tel: +44 20 7710 7600
Walbrook PR (Financial PR & IR) Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 7980 54 1 893 / Mob: +44 7876
741 001
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy in the
treatment of cancer, which harnesses the very best in modern
technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva,
focuses on the development of a proprietary proton accelerator -
LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates
protons to the energy levels achieved in legacy machines but in a
compact and truly modular unit, offering significant cost
advantages. LIGHT also delivers proton beams in a way that
facilitates greater precision and electronic control, which are not
achievable with currently available alternative technologies.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with an innovative
technology, offering better health outcomes and lower treatment
related side effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton or particle therapy and
actively seeks working relationships with providers of these
innovative technologies. Through these relationships, the Company
will remain the prime provider of cutting edge, cost-effective
systems for particle therapy.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMELLFLKFFLBBQ
(END) Dow Jones Newswires
January 22, 2019 10:29 ET (15:29 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024